Pages in this section
The treatment of Spondyloarthritis (SpA) is the same as the treatment outlined for Ankylosing Spondylitis (AS). This essentially involves the combination of exercise therapy and NSAID therapy. There is increasing evidence that the early implementation of therapy can affect the long-term outcomes of the disease with regards to the damage caused and the subsequent impairment in function that results.
The use of anti-TNF therapy to specifically block the driver of inflammation may lead to further additional improvements in these outcomes.
In Australia, these medications are not currently available for the management of undifferentiated SpA or non-radiographic SpA but are available for treating those with AS and Psoriatic Arthritis in whom the inflammatory markers (CRP and ESR) are raised. The specific anti-TNF blocking medications available in Australia include Infliximab (Remicade), Etanercept (Enbrel), Adalimumab (Humira), and Golimumab (Simponi).